Hong Kong stocks surged | Kintor Pharmaceutical-B (09939.HK) rose more than 5% and plans to issue subscription shares at a discount of 15.03% to raise funds for the Phase III clinical trial of KX-826.

According to the 4.1 mandan economics APP, Kai Tuo pharmaceutical - B (09939.HK) rose more than 5%, as of the deadline for the draft, up 5.39%, at 2.15 Hong Kong dollars, with a turnover of 5,544,500 Hong Kong dollars.